flecainide has been researched along with Multiple Sclerosis in 1 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide was also potent in suppressing microglial activation in experimental autoimmune encephalomyelitis." | 5.39 | Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. ( Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM, 2013) |
| "Flecainide was also potent in suppressing microglial activation in experimental autoimmune encephalomyelitis." | 1.39 | Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. ( Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morsali, D | 1 |
| Bechtold, D | 1 |
| Lee, W | 1 |
| Chauhdry, S | 1 |
| Palchaudhuri, U | 1 |
| Hassoon, P | 1 |
| Snell, DM | 1 |
| Malpass, K | 1 |
| Piers, T | 1 |
| Pocock, J | 1 |
| Roach, A | 1 |
| Smith, KJ | 1 |
1 other study available for flecainide and Multiple Sclerosis
| Article | Year |
|---|---|
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Topics: Alanine; Animals; Benzylamines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; | 2013 |